

## ASX ANNOUNCEMENT

### Bod Science Executes an Asset Sale Deed to Sell Intellectual Property Rights

**Sydney, Australia – 24 January 2025:** Cannabis focused drug development and product innovation company BOD Science Limited (Subject to Deed of Company Arrangement) (**BOD Science**) refers to the ASX Announcement dated 26 April 2024 whereby it announced that the Deed of Company Arrangement (**DOCA**) was executed with Biortica Agrimed Limited (**Biortica**) on 24 April 2024.

#### Execution of Asset Sale Deed

The Deed Administrator is pleased to announce that after extensive negotiations BOD Science has executed and completed on an Asset Sale Deed with the Aqua Phase inventors and Optimus Salvus Limited ("**Optimus Salvus**") (an entity incorporated in Gibraltar) (all refer to "**Buyers**") to sell the Company's rights to three (3) intellectual properties ("**IPs**"), including soft gel/S3 clinical research and data, Aqua Phase with its associated data and IP and CLIC Protein IP, to Optimus Salvus, in consideration for a lump sum payment of AU\$125,000 exclusive of GST, the forgiveness of debt claimed by the Aqua Phase inventors in the sum of £2M GBP and a 5% equity interest in Optimus Salvus.

Pursuant to the terms of the Asset Sale Deed, the proceeds of sale of the IP Assets are to form part of a deed fund and to be transferred to the Creditors' Trust following effectuation of the DOCA.

#### About BOD

BOD is a cannabis focused drug development and product innovation company, with a focus on progressing R&D and a deferred clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets. Further information can be found at <https://bodscience.com/>.

**This announcement has been approved by Andrew Barden (Deed Administrator).**

**Ends**

**For more information, please contact:**

Andrew Barnden

Deed Administrator

E: [abarnden@rodgersreidy.com.au](mailto:abarnden@rodgersreidy.com.au)

#### Legal notice

This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "will", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. They may include, without limitation, statements regarding plans, strategies and objectives and anticipated business developments. Forward-looking statements involve known and unknown

risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on BOD's good-faith assumptions as to the financial, market, regulatory and other considerations that exist and affect BOD's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. There may be other factors that could cause actual results or events not to be as anticipated and many events are beyond the reasonable control of BOD. BOD's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Any forward-looking statements in this announcement are only made as at the date of this announcement and, to the maximum extent permitted by law, BOD disclaims any obligation or undertaking to update or revise any forward-looking statements or to advise of any change in assumptions on which any such statement is based.

For personal use only

**CONTACT**

T +61 2 9199 5018  
E [info@bodaustralia.com](mailto:info@bodaustralia.com)

ASX:BOD  
[bodscience.com](http://bodscience.com)

